Medacta Group (SWX:MOVE) - Aktienkurs, Nachrichten und Analyse

MOVE Aktienübersicht

Medacta Group SA entwickelt, produziert und vertreibt orthopädische und neurochirurgische Medizinprodukte in Europa, Nordamerika, im asiatisch-pazifischen Raum und international. Mehr Details

MOVE grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	3/6
Vergangene Leistung	3/6
Finanzielle Gesundheit	5/6
Dividenden	0/6

Belohnungen

Prognostiziertes Gewinnwachstum 18.35% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 13%

Analysten sind sich einig, dass der Aktienkurs um 26.2%

Risikoanalyse

Hat einen hohen Schuldenstand

Medacta Group SA Wettbewerber

Medartis Holding

SWX:MED

CHF 690.7m

Metall Zug

SWX:METN

CHF 499.5m

Straumann Holding

SWX:STMN

CHF 17.8b

Sonova Holding

SWX:SOON

CHF 18.6b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Medacta Group
Historische Aktienkurse
Aktueller Aktienkurs	CHF 110.80
52-Wochen-Hoch	CHF 135.00
52-Wochen-Tief	CHF 107.80
Beta	1.16
11 Monat Veränderung	-2.98%
3 Monate Veränderung	-14.37%
1 Jahr Veränderung	-5.94%
33 Jahre Veränderung	-10.65%
5 Jahre Veränderung	32.06%
Veränderung seit IPO	15.30%

Aktuelle Nachrichten und Updates

The Price Is Right For Medacta Group SA (VTX:MOVE)

Nov 22

Is Medacta Group (VTX:MOVE) A Risky Investment?

Oct 14

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

Sep 06

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Aug 21

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Aug 06

Recent updates

The Price Is Right For Medacta Group SA (VTX:MOVE)

Nov 22

Is Medacta Group (VTX:MOVE) A Risky Investment?

Oct 14

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

Sep 06

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Apr 17

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Mar 29

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Feb 22

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Feb 07

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Dec 18

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Dec 04

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Nov 15

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Oct 30

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Oct 17

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Sep 29

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Aug 11

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Jul 27

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

Jul 03

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Apr 28

Is Medacta Group (VTX:MOVE) A Risky Investment?

Apr 08

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dec 25

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Dec 09

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Nov 09

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

Sep 16

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Aug 20

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Jul 02

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

May 28

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

May 12

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Mar 31

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Mar 17

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Feb 07

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Dec 10

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Nov 05

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Sep 30

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Aug 26

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Jul 20

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

May 19

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Apr 05

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Mar 02

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

Feb 02

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Jan 12

Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Dec 21

Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

Dec 03

Aktionärsrenditen

	MOVE	CH Medical Equipment	CH Markt
7D	-1.9%	0.7%	0.6%
1Y	-5.9%	10.4%	5.8%

Rendite im Vergleich zur Industrie: MOVE unter dem Niveau der Branche Swiss Medical Equipment , die im vergangenen Jahr eine Rendite von 10.4% erzielte.

Rendite vs. Markt: MOVE hinter dem Markt Swiss zurück, der im vergangenen Jahr eine Rendite von 5.8 erzielte.

Preisvolatilität

Is MOVE's price volatile compared to industry and market?
MOVE volatility
MOVE Average Weekly Movement	3.7%
Medical Equipment Industry Average Movement	4.0%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.6%
10% least volatile stocks in CH Market	1.6%

Stabiler Aktienkurs: MOVE hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: MOVEDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1958	1,826	Francesco Siccardi	www.medacta.com

Medacta Group SA entwickelt, produziert und vertreibt orthopädische und neurochirurgische Medizinprodukte in Europa, Nordamerika, im asiatisch-pazifischen Raum und international. Das Unternehmen bietet personalisierte 3D-Planungstools für die Bereiche Hüfte, Knie, Schulter, Gelenkersatz, Sportmedizin und Wirbelsäule an. Die Medacta Group SA wurde 1958 gegründet und hat ihren Hauptsitz in Castel San Pietro, Schweiz.

Medacta Group SA's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Medacta Group im Vergleich zum Marktanteil des Unternehmens?
MOVE grundlegende Statistiken
Marktanteil	CHF 2.21b
Gewinn(TTM)	CHF 52.34m
Umsatz(TTM)	CHF 506.84m

42.2x

Kurs-Gewinn-Verhältnis

4.4x

Kurs-Umsatz-Verhältnis

Ist MOVE zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
MOVE Gewinn- und Verlustrechnung (TTM)
Einnahmen	€544.29m
Kosten der Einnahmen	€174.57m
Bruttogewinn	€369.72m
Sonstige Ausgaben	€313.51m
Umsatz	€56.21m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	2.82
Bruttomarge	67.93%
Nettogewinnspanne	10.33%
Schulden/Eigenkapital-Verhältnis	54.1%

Wie hat sich MOVE auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

0.5%

Aktuelle Dividendenrendite

21%

Ausschüttungsquote

MOVE Aktienübersicht

Belohnungen

Risikoanalyse

Medacta Group SA Wettbewerber

SWX:MED

CHF 690.7m

SWX:METN

CHF 499.5m

SWX:STMN

CHF 17.8b

SWX:SOON

CHF 18.6b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

The Price Is Right For Medacta Group SA (VTX:MOVE)

Is Medacta Group (VTX:MOVE) A Risky Investment?

First half 2024 earnings released: EPS: €1.91 (vs €1.46 in 1H 2023)

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Recent updates

The Price Is Right For Medacta Group SA (VTX:MOVE)

Is Medacta Group (VTX:MOVE) A Risky Investment?

First half 2024 earnings released: EPS: €1.91 (vs €1.46 in 1H 2023)

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Now 20% undervalued after recent price drop

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dividend of CHF0.55 announced

Full year 2023 earnings: EPS and revenues miss analyst expectations

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Insufficient new directors

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Medacta Group SA to Report Q4, 2023 Results on Feb 02, 2024

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

First half 2023 earnings released: EPS: €1.46 (vs €1.28 in 1H 2022)

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Upcoming dividend of CHF0.54 per share at 0.5% yield

Is Medacta Group (VTX:MOVE) A Risky Investment?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Medacta Group SA to Report Fiscal Year 2022 Results on Feb 03, 2023

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Medacta Group SA to Report Q2, 2023 Results on Sep 22, 2023

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

First half 2022 earnings released: EPS: €1.28 (vs €1.49 in 1H 2021)

Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Medacta Group SA Provides Revenue Guidance for the Year 2022

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group SA Approves Distribution

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Consensus forecasts updated

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Full year 2021 earnings: EPS misses analyst expectations

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Medacta Launches 360° (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS €1.49 (vs €0.48 in 1H 2020)

Medacta Group SA Confirms Revenue Guidance for the Year 2021

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Medacta Announces Successful Completion of First Reverse Shoulder Arthroplasties Using NextAR Augmented Reality Surgical Platform

Erträge & Einnahmen